Pan American Health Organization selects Brazil and Argentina to produce mRNA vaccines for Latin America

In a statement the Pan American Health Organization (PAHO) said, it has selected two biomedical centers in Brazil and in Argentina to develop and produce mRNA-based vaccines to fight COVID-19 in Latin America.

PAHO is the region’s health agency.

The health agency  aims to tap existing manufacturing capacities to help transfer vaccine technology developed by Moderna in the United States to a region significantly affected by the coronavirus and still continues to be without access to sufficient vaccines.

Brazil’s premier biomedical lab, the Bio-Manguinhos Institute of Technology on Immunobiologicals at Fiocruz, has been picked for its history of vaccine manufacturing.

PAHO has also selected Sinergium Biotech, a private sector biopharmaceutical company, as its resource center in Argentina. It will also partner with pharmaceutical lab mAbxience of the same group to develop and manufacture active vaccine ingredients.

The Americas region has borne the brunt of COVID-19 infections to date, with 87.6 million cases recorded and over 2.16 million deaths. Despite these high numbers, vaccine distribution continues to be unequal, said PAHO with very few countries in the region managing to reach the year-end 40% vaccine target set by the WHO.



Categories: Creativity, Economy & Finance, Entrepreneurship, HR & Organization, Strategy, Sustainability

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: